Search
for
Sort by
Research 61–90 of 352
- Sorafenib-induced Facial Acneiform Eruption
- Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
- The PDGF/PDGFR pathway as a drug target
- Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
- Targeted Treatments of Non-Small Cell Lung Cancer (NSCLC): Skin Toxicity
- BAYONET trial: staged combination with encorafenib, binimetinib, plus cetuximab following encorafenib plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer
- Keratosis Pilaris-like Eruption during Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors: Literature Review and Report of a Case Related to Imatinib
- Oncogenic senescence: a multi-functional perspective
- Regulation of melanocyte stem cell behavior by the niche microenvironment
- Male androgenetic alopecia (Part II)
- Aberrant Activation of the Hedgehog Pathway in Cutaneous Melanoma: Therapeutic Potential of Pharmacological Inhibitors
- Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology
- Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies
- Persistently curly hair phenotype with the use of nivolumab for squamous cell lung cancer
- IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes
- Diagnosis and Management of Melanoma of the Scalp: A Review of the Literature
- Resolution of paraneoplastic alopecia areata following nivolumab in a patient with metastatic melanoma
- Poster Presentations at the 28th Joint Meeting of the International Society of Dermatopathology, March 5–6, 2025, Orlando, Florida, USA
- Spotlight commentary: Navigating the cutaneous side effects of chemotherapy
- 612 Wnt signaling induces fibrotic fat loss via DPP4 in skin fibrosis
- Poster Presentations
- Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy
- The Aldo-Keto Reductase AKR1B10 Is Up-Regulated in Keloid Epidermis, Implicating Retinoic Acid Pathway Dysregulation in the Pathogenesis of Keloid Disease
- Targeting the Hippo/YAP/TAZ signalling pathway: Novel opportunities for therapeutic interventions into skin cancers
- Nilotinib-induced generalized keratosis pilaris: Report of a rare case
- Exploiting the origins of Ras mediated squamous cell carcinoma to develop novel therapeutic interventions
- Estimating the Effect of Finasteride on Kallikrein Marker Levels in Blood and the Use of Converted Markers in the Four-Kallikrein Model
- Cutaneous reactions to targeted therapies in children with CNS tumors: A cross‐sectional study
- Cutaneous Toxicities of Advanced Treatment for Cutaneous Melanoma: A Prospective Study from a Single-Center Institution
- Drug Repurposing against KRAS Mutant G12C: A Machine Learning, Molecular Docking, and Molecular Dynamics Study